* Windtree Therapeutics Inc reported a quarterly adjusted loss of $5.54 per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -86 cents. The lone analyst forecast for the quarter was for a loss of $2.27 per share.
* Reported revenue was zero; analysts expected zero.
* Windtree Therapeutics Inc's reported EPS for the quarter was a loss of $4.23.
* The company reported a quarterly loss of $3.75 million.
* Windtree Therapeutics Inc shares had fallen by 76.7% this quarter and lost 95.7% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "hold"
Wall Street's median 12-month price target for Windtree Therapeutics Inc is $7.00 This summary was machine generated from LSEG data November 26 at 10:54 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -2.27 -5.54 Missed
Jun. 30 2024 -8.11 -20.91 Missed
Dec. 31 2023 -0.94 -0.74 Beat
Comments